title: P2Y purinoceptors as potential emerging therapeutical target in vascular disease.
abstract: In the last two decades a tremendous development has been noticed in our understanding of the purinergic system, consisting of heterogeneously expressed purinoceptor subtypes and its classical agonists: e.g., adenosine triphosphate, uridine triphosphate or complex dinucleoside polyphosphates. These agonists exert multiple effects on the vascular system: they regulate the relaxation and constriction of arterial blood vessels, lead to proliferation and migration in endothelial cells and vascular smooth muscle cells, and mediate potent proinflammatory responses or phenotypic cell changes. This review focuses on the P2 purinoceptor subtype P2Y and its pleiotropic effects in the vascular wall under physiological and pathophysiological condition. Various experimental and clinical studies provide evidence that pharmacological targeting of P2Y might be effective in reducing vascular alterations under disease conditions.
authors.affiliation: Charité -Universitätsmedizin Berlin, CharitéCentrum, Department of Nephrology, Campus Benjamin Franklin, Berlin, Germany. Markus.vanderGiet@charite.de
authors.forename: Mirjam
authors.initials: M
authors.lastname: Schuchardt
authors.forename: Markus
authors.initials: M
authors.lastname: Tölle
authors.forename: Markus
authors.initials: M
authors.lastname: van der Giet
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000737:chemistry / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D008024:Ligands; D058921:Purinergic P2Y Receptor Antagonists / Q000737:chemistry / Q000494:pharmacology*; D058470:Receptors, Purinergic P2Y / Q000187:drug effects* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014652:Vascular Diseases / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D002317:Cardiovascular Agents; D008024:Ligands; D058921:Purinergic P2Y Receptor Antagonists; D058470:Receptors, Purinergic P2Y